OncoMatch/Clinical Trials/NCT06007924
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Is NCT06007924 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Avutometinib and Defactinib for thyroid cancer.
Treatment: Avutometinib · Defactinib — The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. The researchers will also test whether avutometinib and defactinib is a safe treatment that causes few or mild side effects.
Check if I qualifyExtracted eligibility criteria
Cancer type
Thyroid Cancer
Biomarker criteria
Required: BRAF Class 2 or 3 alteration (non-V600E/K mutations or rearrangements)
Class 2 or 3 BRAF alterations (non-V600E/K mutations or rearrangements)
Required: RAS mutation
RAS mutation
Required: NF1 mutation
NF1 mutation
Required: RET rearrangement
RET rearrangement
Required: NTRK1 rearrangement
NTRK rearrangement
Required: NTRK2 rearrangement
NTRK rearrangement
Required: NTRK3 rearrangement
NTRK rearrangement
Required: ALK rearrangement
ALK rearrangement
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: MEK inhibitor
Exception: patients who received these therapies for a defined period of time to enhance radioiodine activity
Prior therapy with a MEK 1/2 inhibitor
Cannot have received: BRAF inhibitor (Class II/III)
Exception: patients who received these therapies for a defined period of time to enhance radioiodine activity
inhibitor that targets Class II/Class III BRAF alterations
Cannot have received: FAK inhibitor
Exception: patients who received these therapies for a defined period of time to enhance radioiodine activity
FAK inhibitor
Cannot have received: systemic investigational anti-cancer therapy
systemic investigational anti-cancer therapy within 4 weeks of the first dose of study therapy
Lab requirements
Blood counts
WBC ≥ 2000/μL; Neutrophils ≥ 1000/μL; Platelets ≥ 100 x10^3 /μL; Hemoglobin > 9.0 g/dL
Kidney function
Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 50 mL/min
Liver function
AST/ALT ≤ 2.5 x ULN (or < 5x ULN in patients with liver metastases); Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
Cardiac function
Baseline QTc interval < 460 ms for women and ≤450 ms for men using Frederica's QT correction formula; left ventricular ejection fraction >50% by ECHO or MUGA
Screening laboratory values must meet the following criteria: WBC ≥ 2000/μL; Neutrophils ≥ 1000/μL; Platelets ≥ 100 x10^3 /μL; Hemoglobin > 9.0 g/dL; AST/ALT ≤ 2.5 x ULN (or < 5x ULN in patients with liver metastases); Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL); Albumin ≥ 3.0 g/dL; Creatine phosphokinase (CPK) ≤ 2.5 x ULN; Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 50 mL/min; Baseline QTc interval < 460 ms for women and ≤450 ms for men using Frederica's QT correction formula; left ventricular ejection fraction >50% by ECHO or MUGA
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify